Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020113403 - CYTOKINE FUSION PROTEINS

Publication Number WO/2020/113403
Publication Date 11.06.2020
International Application No. PCT/CN2018/119071
International Filing Date 04.12.2018
IPC
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C07K 14/55 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
55IL-2
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • BEIJING PERCANS ONCOLOGY CO. LTD. [CN]/[CN]
Inventors
  • CHEN, Yiyou
  • GUO, Dagang
Agents
  • WU, FENG & ZHANG
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYTOKINE FUSION PROTEINS
(FR) PROTÉINES DE FUSION DE CYTOKINES
Abstract
(EN)
Provided are cytokine fusion proteins comprising a first cytokine fused to a second cytokine, for example, interleukin-2 (IL-2) or interferon-β (IFN-β) fused to the N-terminus of tumor necrosis factor-α (TNF-α), and related compositions and methods of use thereof for treating cancers, either as standalone agents or in combination with autologous tumor vaccines and/or immune checkpoint modulatory agents
(FR)
L'invention concerne des protéines de fusion de cytokines comprenant une première cytokine fusionnée à une seconde cytokine, par exemple, l'interleukine-2 (IL-2) ou l'interféron-β (IFN-β) fusionné à l'extrémité N-terminale du facteur de nécrose tumorale α (TNF-α), ainsi que des compositions associées et leurs procédés d'utilisation pour traiter des cancers, en tant qu'agents seuls, ou en combinaison avec des vaccins antitumoraux autologues et/ou des agents modulateurs de points de contrôle immunitaires.
Latest bibliographic data on file with the International Bureau